Incretin Atlas › Trials › Ribupatide T2D phase 3 after metformin +/- SGLT2i (NCT06649344)
Ribupatide T2D phase 3 after metformin +/- SGLT2i (NCT06649344)
Ribupatide (HRS9531) · t2d
Design
- Molecule(s)
- Ribupatide (HRS9531)
- Population
- t2d
- Official title
- A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Phase
- 3
- Registry status
- completed · 2024-10 → 2026-07
- Participants
- 884
- Duration
- 36 weeks
- Registry
- NCT06649344
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 mg vs semaglutide 1 mg: HbA1c -2.29 | t2d china | 36 | — | — | — | −2.8 | — | — | — | — | — | — | press release |
| 2 mg vs semaglutide 1 mg: HbA1c -2.29 | t2d china | 36 | — | — | — | −2.3 | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (2)
- 4 mg · hba1c · press release
the mean HbA1c reductions in the ribupatide injection 4 mg and 2 mg groups reached 2.78% and 2.34%, respectively, compared to 2.29% in the semaglutide injection 1 mg group
- 2 mg · hba1c · press release
the mean HbA1c reductions in the ribupatide injection 4 mg and 2 mg groups reached 2.78% and 2.34%, respectively, compared to 2.29% in the semaglutide injection 1 mg group
Primary sources
- Kailera. Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates (8-K Ex. 99.1) [press release]. 2026-08-12. Available from: https://www.sec.gov/Archives/edgar/data/2096997/000119312526346919/ck0002096997-ex99_1.htm
- ClinicalTrials.gov NCT06649344
How to cite this page
Medical Adviser's Group. Incretin Atlas: Ribupatide T2D phase 3 after metformin +/- SGLT2i (NCT06649344). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/ribupatide-t2d-phase-3-after-metformin-sglt2i/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.